Technical Analysis for ARQL - ArQule, Inc.

Grade Last Price % Change Price Change
grade C 10.6 2.61% 0.27
ARQL closed up 2.61 percent on Thursday, July 18, 2019, on 46 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Jul 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ARQL trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 2.61%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.61%
Stochastic Reached Oversold Weakness 2.61%
Oversold Stochastic Weakness 2.61%
1,2,3 Pullback Bullish Bullish Swing Setup -0.19%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.19%

Older signals for ARQL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company is also involved in the development of ARQ 087, an inhibitor of fibroblast growth factor receptor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases, which are in Phase 1 clinical development, as well as ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.
Chemistry Biotechnology Cancer Disease Organic Chemistry Colorectal Cancer Cancer Therapies Ethers Cancer Therapeutics Tyrosine Kinase Inhibitors Tyrosine Kinase Kinase C Met Treatment Of Colorectal Cancer
Is ARQL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.22
52 Week Low 2.23
Average Volume 3,736,155
200-Day Moving Average 5.288
50-Day Moving Average 8.5884
20-Day Moving Average 10.8575
10-Day Moving Average 10.87
Average True Range 0.5815
ADX 39.6
+DI 24.7482
-DI 14.9447
Chandelier Exit (Long, 3 ATRs ) 10.4755
Chandelier Exit (Short, 3 ATRs ) 10.9145
Upper Bollinger Band 11.7235
Lower Bollinger Band 9.9915
Percent B (%b) 0.35
BandWidth 15.952107
MACD Line 0.6039
MACD Signal Line 0.8279
MACD Histogram -0.224
Fundamentals Value
Market Cap 754.43 Million
Num Shares 71.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -27.89
Price-to-Sales 29.83
Price-to-Book 7.11
PEG Ratio -0.47
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.45
Resistance 3 (R3) 11.43 11.12 11.31
Resistance 2 (R2) 11.12 10.90 11.13 11.26
Resistance 1 (R1) 10.86 10.77 10.99 10.88 11.21
Pivot Point 10.56 10.56 10.62 10.57 10.56
Support 1 (S1) 10.30 10.34 10.43 10.32 9.99
Support 2 (S2) 9.99 10.21 10.00 9.94
Support 3 (S3) 9.73 9.99 9.89
Support 4 (S4) 9.75